$263.64
-0.40%Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
COR โข NYSE
| Cencora, Inc. Cash Flow Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | Sep 2007 | Sep 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
1.6B | 1.5B | 1.7B | 1.7B | 1.5B | -3.4B | 854.1M | 1.7B | 364.5M | 1.4B | 34.7M | 284M | 493.4M | 761.4M | 706.6M | 636.7M | 511.9M | 469.1M | 469.2M | 467.7M | |
0.0 | 448.2M | 980.8M | 709.8M | 514.8M | 408M | 497.5M | 510.1M | 422.9M | 392.2M | 256M | 196.6M | 170.8M | 142M | 121.2M | 99.2M | 94.3M | 95.9M | 104.3M | 96.9M | |
0.0 | -102.3M | -118.9M | 196.2M | 334.9M | -1.5B | 28.5M | -795.5M | 319.1M | -130.9M | 20.8M | 39.3M | 25.6M | 61.3M | 195M | 85.5M | 84.3M | 62.1M | 13.2M | 92.1M | |
0.0 | 148M | 124.6M | 93.4M | 99.6M | 74.4M | 58.9M | 62.3M | 62.2M | 65M | 60.9M | 43.1M | 36.3M | 26.1M | 28.4M | 30.8M | 27.1M | 25.5M | 0.0 | 0.0 | |
2.3B | 1.2B | 304.9M | 176.8M | -194.6M | 4.8M | 541.6M | 178.2M | -131.7M | 396.1M | 1.3B | 464.4M | 200M | 13.4M | 49.4M | 64.4M | 40.9M | 46.7M | 102.8M | 32.4M | |
35.4M | 298.7M | 874.5M | -139.7M | 367.3M | 6.7B | 363.4M | -202.1M | 467.2M | 1B | 2.2B | 435.7M | -138M | 301.3M | 67.4M | 191.9M | 25.2M | 37.8M | 518.4M | 118.1M | |
3.9B | 3.5B | 3.9B | 2.7B | 2.7B | 2.2B | 2.3B | 1.4B | 1.5B | 3.2B | 3.9B | 1.5B | 788.1M | 1.3B | 1.2B | 1.1B | 783.8M | 737.1M | 1.2B | 807.3M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-668M | -487.2M | -458.4M | -496.3M | -438.2M | -369.7M | -310.2M | -336.4M | -466.4M | -464.6M | -231.6M | -264.5M | -202.5M | -164M | -168M | -184.6M | -145.8M | -137.3M | -118.1M | -113.1M | |
(0.0) | (0.0) | (0.0) | (120.3M) | -5.7B | -56.1M | -64M | -785.3M | -61.6M | -2.8B | -2.6B | -9.1M | (330M) | -775.7M | -45.4M | (0.0) | -1.5M | -166.2M | -170.1M | -296.2M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -56.1M | (0.0) | (0.0) | -48.6M | -61.1M | -86.2M | -117.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -7.7B | -2B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -307.4M | 0.0 | 0.0 | 74.8M | 101.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 108K | 467.4M | 7.3B | 2.3B | |
-4.3B | -130.9M | -2.1B | 7.6M | 22.3M | 409.3M | -1.7M | 10.6M | 3.9M | 5.1M | 20M | 7.2M | -10.3M | -8.2M | 0.0 | 0.0 | -1M | -479K | 13.3M | 77.8M | |
-5B | -618.1M | -2.6B | -368.4M | -6.1B | -379.9M | -375.8M | -1.1B | -498M | -3.2B | -2.9B | -384.2M | (117.3M) | -947.9M | -212.4M | -184.4M | -148.3M | (163.4M) | -674.4M | -42.7M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-406.3M | -1.5B | -1.1B | -389.8M | 116.6M | -354.1M | -674M | -639.2M | -329.9M | -2.3B | -1.9B | -753.9M | -484.2M | -1.2B | -840.6M | -470.4M | -450.4M | -679.7M | -1.3B | -581.2M | |
3.2B | -385.5M | -623.3M | -923.1M | 2.2B | -32M | -133.1M | 635.7M | -749.6M | 713.2M | 1.5B | 566.4M | 0.0 | 52M | -42K | 178.6M | -8.8M | -16.4M | 224.1M | 131.9M | |
-437.1M | -416.2M | -398.8M | -391.7M | -366.6M | -343.6M | -339M | -333M | -320.3M | -288.5M | -253.9M | -214.5M | -195.7M | -132.8M | -117.6M | -90.6M | -62.7M | -48.7M | -37.2M | -20.6M | |
-435.5M | -1.5B | -1.2B | -483.7M | -82.2M | -420.4M | -674M | -639.2M | -329.9M | -2.3B | -1.9B | -753.9M | -484.2M | -1.2B | -840.6M | -470.4M | -450.4M | -680.6M | -1.4B | -719.2M | |
-103.1M | -75.8M | -80.7M | -48.2M | -13.7M | 126.1M | -16.7M | -44.7M | 86.9M | 2.4B | -15.5M | -227.4M | -216.8M | 10.9M | 15M | -25.8M | 17.7M | -1.3M | 0.0 | 0.0 | |
2.2B | -2.3B | -2.2B | -1.8B | 2B | -603.6M | -1.1B | -242.9M | -1.3B | 565.1M | -632.1M | -501.5M | -741M | -1.1B | -787.7M | -275.4M | -504.2M | -662.6M | -1.2B | -469.8M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
-50.3M | 9.4M | 72.8M | -57.9M | -3.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 966.6M | |
1.1B | 545M | -840.7M | 523.4M | -1.5B | 1.2B | 881.7M | 57.4M | -321.8M | 574.4M | 358.9M | 577.5M | 164.4M | -759.4M | 167.8M | 648.8M | 131.3M | 237.9M | -621.1M | 294.7M | |
3.3B | 2.8B | 3.6B | 3.1B | 4.6B | 3.4B | 2.5B | 2.4B | 2.7B | 2.2B | 1.8B | 1.2B | 1.1B | 1.8B | 1.7B | 1B | 878.1M | 640.2M | 1.3B | 966.6M | |
4.4B | 3.3B | 2.8B | 3.6B | 3.1B | 4.6B | 3.4B | 2.5B | 2.4B | 2.7B | 2.2B | 1.8B | 1.2B | 1.1B | 1.8B | 1.7B | 1B | 878.1M | 640.2M | 1.3B | |
3.2B | 3B | 3.5B | 2.2B | 2.2B | 1.8B | 2B | 1.1B | 1B | 2.7B | 3.7B | 1.2B | 585.7M | 1.1B | 1,000M | 924M | 637.9M | 599.8M | 1.1B | 694.1M |
COR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 23, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 18, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 |
Continue your COR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.